 This is a Bloomberg Money Minute. Drug giant Eli Lilly, maker of the blockbuster weight loss drug Zepbound, is close to getting another breakthrough medication approved by the FDA, Denonimab, to treat the 2 million U.S. patients in the early stages of Alzheimer's disease. At Lilly, we're driven to uncover the next great discovery. And while Denonimab would compete against a similar drug, Lekembe, made by Biogen and a partner approved in 2023, Lilly has been working on its Alzheimer's medication for years.